GlassScriptPhysician profile
Thomas Venkat Mallidi
NPI 1588924278
$1,132.74
in general payments reported to CMS, 2019-2025
19 companies · $14.44 in 2025
The $14.44 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,041 · 2022: $13.11 · 2023: $42.08 · 2024: $21.94 · 2025: $14.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $78.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $78.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $206.39 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $173.75 | 2019-2022 | |
| Pfizer INC. | $158.23 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.47 | 2019 | |
| Novo Nordisk INC | $88.17 | 2019 | |
| Glaxosmithkline, LLC. | $58.64 | 2019-2025 | Bexsero, Pediarix |
| Lilly USA, LLC | $42.08 | 2023 | Mounjaro |
| Teva Pharmaceuticals USA, INC. | $36.94 | 2019 | |
| Abbvie INC. | $36.11 | 2019 | |
| Amgen INC. | $30.16 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.69 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $24.67 | 2019 | |
| Arbor Pharmaceuticals, INC. | $23.90 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.94 | 2024 | |
| Amarin Pharma, INC. | $21.62 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $19.93 | 2019 | |
| Novartis Pharmaceuticals Corporation | $17.18 | 2019 | |
| Allergan, INC. | $13.50 | 2019 | |
| Merck Sharp & Dohme LLC | $11.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Mallidi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.